Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Hodgkin’s Lymphoma – Epidemiology – Epidemiology – Hodgkin’s Lymphoma – Mature Markets
Clarivate Epidemiology’s coverage of Hodgkin’s lymphoma (HL) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | China In-Depth | China | 2021
Of the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China’…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape & Forecast | G7 | 2021
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Current Treatment: Physician Insights | US | 2021
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for B-cell…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Access & Reimbursement | US | 2021
Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses, and the treatment landscape is entrenched with targeted agents. Roche’s Rituxan, Janssen / AbbVie’s…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2020
The launch of several novel therapies and multiple label expansions of premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-year…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | China In-Depth | China | 2020
Among the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma DLBCL is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2019
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over the ten-…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | Relapsed or Refractory DLBCL | US/EU | 2019
MARKET OUTLOOK Relapsed/refractory diffuse large B-cell lymphoma (R/RDLBCL) represents an area of high unmet need in non-Hodgkin’s lymphoma (NHL) due to the poor outcomes with current salvage…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Current Treatment: Physician Insights | US | 2019
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for NHL…
